Literature DB >> 25712723

Exposure to experimental preeclampsia in mice enhances the vascular response to future injury.

Dafina Pruthi1, Eliyahu V Khankin1, Robert M Blanton1, Mark Aronovitz1, Suzanne D Burke1, Amy McCurley1, S Ananth Karumanchi2, Iris Z Jaffe2.   

Abstract

Cardiovascular disease (CVD) remains the leading killer of women in developed nations. One sex-specific risk factor is preeclampsia, a syndrome of hypertension and proteinuria that complicates 5% of pregnancies. Although preeclampsia resolves after delivery, exposed women are at increased long-term risk of premature CVD and mortality. Pre-existing CVD risk factors are associated with increased risk of developing preeclampsia but whether preeclampsia merely uncovers risk or contributes directly to future CVD remains a critical unanswered question. A mouse preeclampsia model was used to test the hypothesis that preeclampsia causes an enhanced vascular response to future vessel injury. A preeclampsia-like state was induced in pregnant CD1 mice by overexpressing soluble fms-like tyrosine kinase-1, a circulating antiangiogenic protein that induces hypertension and glomerular disease resembling human preeclampsia. Two months postpartum, soluble fms-like tyrosine kinase-1 levels and blood pressure normalized and cardiac size and function by echocardiography and renal histology were indistinguishable in preeclampsia-exposed compared with control mice. Mice were then challenged with unilateral carotid injury. Preeclampsia-exposed mice had significantly enhanced vascular remodeling with increased vascular smooth muscle cell proliferation (180% increase; P<0.01) and vessel fibrosis (216% increase; P<0.001) compared with control pregnancy. In the contralateral uninjured vessel, there was no difference in remodeling after exposure to preeclampsia. These data support a new model in which vessels exposed to preeclampsia retain a persistently enhanced vascular response to injury despite resolution of preeclampsia after delivery. This new paradigm may contribute to the substantially increased risk of CVD in woman exposed to preeclampsia.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  VEGF receptor flt-1 protein; cardiovascular diseases; hypertension; preeclampsia; vascular remodeling

Mesh:

Year:  2015        PMID: 25712723      PMCID: PMC4359068          DOI: 10.1161/HYPERTENSIONAHA.114.04971

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  38 in total

1.  LATE VASCULAR EFFECTS OF TOXEMIA OF PREGNANCY.

Authors:  F H EPSTEIN
Journal:  N Engl J Med       Date:  1964-08-20       Impact factor: 91.245

Review 2.  The association between preeclampsia and arterial stiffness.

Authors:  Anaïs Hausvater; Tania Giannone; Yessica-Haydee Gomez Sandoval; Robert J Doonan; Constantine N Antonopoulos; Ioannis L Matsoukis; Eleni T Petridou; Stella S Daskalopoulou
Journal:  J Hypertens       Date:  2012-01       Impact factor: 4.844

3.  Preeclampsia: an endothelial cell disorder.

Authors:  J M Roberts; R N Taylor; T J Musci; G M Rodgers; C A Hubel; M K McLaughlin
Journal:  Am J Obstet Gynecol       Date:  1989-11       Impact factor: 8.661

Review 4.  Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension.

Authors:  Florian Herse; Babbette LaMarca
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

5.  Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study.

Authors:  Sajid Shahul; Julie Rhee; Michele R Hacker; Gaurav Gulati; John D Mitchell; Phil Hess; Feroze Mahmood; Zolt Arany; Sarosh Rana; Daniel Talmor
Journal:  Circ Cardiovasc Imaging       Date:  2012-08-13       Impact factor: 7.792

6.  Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors.

Authors:  Dafina Pruthi; Amy McCurley; Mark Aronovitz; Carol Galayda; S Ananth Karumanchi; Iris Z Jaffe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-12-05       Impact factor: 8.311

7.  Long-term alterations in maternal plasma proteome after sFlt1-induced preeclampsia in mice.

Authors:  Egle Bytautiene; Nataliya Bulayeva; Geeta Bhat; Li Li; Kevin P Rosenblatt; George R Saade
Journal:  Am J Obstet Gynecol       Date:  2013-03-13       Impact factor: 8.661

8.  Mouse model of arterial injury.

Authors:  V Lindner; J Fingerle; M A Reidy
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

9.  Elevated blood pressure in pregnancy and subsequent chronic disease risk.

Authors:  Tuija Männistö; Pauline Mendola; Marja Vääräsmäki; Marjo-Riitta Järvelin; Anna-Liisa Hartikainen; Anneli Pouta; Eila Suvanto
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690

10.  Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis.

Authors:  B M Sibai; A el-Nazer; A Gonzalez-Ruiz
Journal:  Am J Obstet Gynecol       Date:  1986-11       Impact factor: 8.661

View more
  22 in total

1.  Echoes of Preeclampsia: Can Echocardiography Help Predict Recurrence?

Authors:  Eliyahu V Khankin; Zoltan Arany
Journal:  Hypertension       Date:  2016-02-22       Impact factor: 10.190

2.  Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.

Authors:  Suzanne D Burke; Zsuzsanna K Zsengellér; Eliyahu V Khankin; Agnes S Lo; Augustine Rajakumar; Jennifer J DuPont; Amy McCurley; Mary E Moss; Dongsheng Zhang; Christopher D Clark; Alice Wang; Ellen W Seely; Peter M Kang; Isaac E Stillman; Iris Z Jaffe; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

Review 3.  Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis.

Authors:  Kathryn J Gray; Richa Saxena; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2017-11-11       Impact factor: 8.661

4.  Maternal serum uric acid concentration is associated with the expression of tumour necrosis factor-α and intercellular adhesion molecule-1 in patients with preeclampsia.

Authors:  J Zhao; D-Y Zheng; J-M Yang; M Wang; X-T Zhang; L Sun; X-G Yun
Journal:  J Hum Hypertens       Date:  2015-10-29       Impact factor: 3.012

Review 5.  National Heart, Lung, and Blood Institute Working Group Report on Salt in Human Health and Sickness: Building on the Current Scientific Evidence.

Authors:  Young S Oh; Lawrence J Appel; Zorina S Galis; David A Hafler; Jiang He; Amanda L Hernandez; Bina Joe; S Ananth Karumanchi; Christine Maric-Bilkan; David Mattson; Nehal N Mehta; Gwendolyn Randolph; Michael Ryan; Kathryn Sandberg; Jens Titze; Eser Tolunay; Glenn M Toney; David G Harrison
Journal:  Hypertension       Date:  2016-06-20       Impact factor: 10.190

6.  Impact of Immune Deficiency on Remodeling of Maternal Resistance Vasculature 4 Weeks Postpartum in Mice.

Authors:  Elizabeth A Bonney; Ann Howard; Kendall Krebs; Kelly Begin; Kelsey Veilleux; Natalia I Gokina
Journal:  Reprod Sci       Date:  2017-01-19       Impact factor: 3.060

Review 7.  Immune Regulation in Pregnancy: A Matter of Perspective?

Authors:  Elizabeth A Bonney
Journal:  Obstet Gynecol Clin North Am       Date:  2016-10-14       Impact factor: 2.844

Review 8.  Preeclampsia and Pregnancy-Related Hypertensive Disorders.

Authors:  S Ananth Karumanchi; Joey P Granger
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

9.  Exposure to placental ischemia impairs postpartum maternal renal and cardiac function in rats.

Authors:  Nina D Paauw; Jaap A Joles; Frank T Spradley; Bhavisha Bakrania; Zsuzsanna K Zsengeller; Arie Franx; Marianne C Verhaar; Joey P Granger; A Titia Lely
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-02-15       Impact factor: 3.619

Review 10.  Pre-eclampsia: pathogenesis, novel diagnostics and therapies.

Authors:  Elizabeth A Phipps; Ravi Thadhani; Thomas Benzing; S Ananth Karumanchi
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.